Does the media favor AVCT or ONT?

In the previous week, Oxford Nanopore Technologies had 9 more articles in the media than Avacta Group. MarketBeat recorded 10 mentions for Oxford Nanopore Technologies and 1 mentions for Avacta Group. Avacta Group's average media sentiment score of 0.00 beat Oxford Nanopore Technologies' score of -0.23 indicating that Avacta Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oxford Nanopore Technologies 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OXB or AVCT?

In the previous week, Oxford Biomedica and Oxford Biomedica both had 1 articles in the media. Oxford Biomedica's average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Biomedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ERGO or AVCT?

Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 42.59%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Ergomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, ERGO or AVCT?

Ergomed has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ergomed £152.09M 0.00 £15M £0.29 N/A Avacta Group £113K 2,878.88 -£30.08M -£9.66 N/A

Is ERGO or AVCT more profitable?

Ergomed has a net margin of 9.87% compared to Avacta Group's net margin of -33,961.06%. Ergomed's return on equity of 18.08% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets Ergomed 9.87% 18.08% 10.16% Avacta Group -33,961.06% -2,929.47% -21.80%

Do analysts prefer SLN or AVCT?

Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 42.59%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer HZD or AVCT?

Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 42.59%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Avacta Group (AVCT) Competitors

GBX 69.43 +0.93 (+1.36%)

As of 07/13/2026 12:03 PM Eastern

Compare

AVCT vs. ONT, OXB, ERGO, SLN, and HZD

Should you buy Avacta Group stock or one of its competitors? MarketBeat compares Avacta Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avacta Group include Oxford Nanopore Technologies (ONT), Oxford Biomedica (OXB), Ergomed (ERGO), Silence Therapeutics (SLN), and Horizon Discovery Group plc (HZD.L) (HZD). These companies are all part of the "biotechnology" industry.

How does Avacta Group compare to Oxford Nanopore Technologies?

Avacta Group (LON:AVCT) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

3.1% of Avacta Group shares are owned by institutional investors. Comparatively, 16.4% of Oxford Nanopore Technologies shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Avacta Group has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Avacta Group currently has a consensus price target of GBX 99, indicating a potential upside of 42.59%. Oxford Nanopore Technologies has a consensus price target of GBX 212.60, indicating a potential upside of 95.06%. Given Oxford Nanopore Technologies' higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oxford Nanopore Technologies has a net margin of -64.85% compared to Avacta Group's net margin of -33,961.06%. Oxford Nanopore Technologies' return on equity of -29.43% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Avacta Group has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,878.88	-£30.08M	-£9.66	N/A
Oxford Nanopore Technologies	£223.90M	4.75	-£175.21M	-£15.10	N/A

In the previous week, Oxford Nanopore Technologies had 9 more articles in the media than Avacta Group. MarketBeat recorded 10 mentions for Oxford Nanopore Technologies and 1 mentions for Avacta Group. Avacta Group's average media sentiment score of 0.00 beat Oxford Nanopore Technologies' score of -0.23 indicating that Avacta Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Nanopore Technologies	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avacta Group and Oxford Nanopore Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Avacta Group compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, Oxford Biomedica and Oxford Biomedica both had 1 articles in the media. Oxford Biomedica's average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 3.1% of Avacta Group shares are owned by institutional investors. 34.8% of Oxford Biomedica shares are owned by company insiders. Comparatively, 47.7% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oxford Biomedica has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Avacta Group has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.69	-£143.51M	-£26.92	N/A
Avacta Group	£113K	2,878.88	-£30.08M	-£9.66	N/A

Oxford Biomedica presently has a consensus price target of GBX 600.04, indicating a potential downside of 8.25%. Avacta Group has a consensus price target of GBX 99, indicating a potential upside of 42.59%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Oxford Biomedica has a net margin of -17.85% compared to Avacta Group's net margin of -33,961.06%. Oxford Biomedica's return on equity of -48.56% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

Summary

Avacta Group beats Oxford Biomedica on 7 of the 13 factors compared between the two stocks.

How does Avacta Group compare to Ergomed?

Ergomed (LON:ERGO) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Ergomed has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ergomed	£152.09M	0.00	£15M	£0.29	N/A
Avacta Group	£113K	2,878.88	-£30.08M	-£9.66	N/A

Ergomed has a net margin of 9.87% compared to Avacta Group's net margin of -33,961.06%. Ergomed's return on equity of 18.08% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ergomed	9.87%	18.08%	10.16%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

Ergomed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

In the previous week, Avacta Group had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Ergomed. Ergomed's average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score.

Company	Overall Sentiment
Ergomed	Neutral
Avacta Group	Neutral

71.1% of Ergomed shares are owned by institutional investors. Comparatively, 3.1% of Avacta Group shares are owned by institutional investors. 18.2% of Ergomed shares are owned by company insiders. Comparatively, 47.7% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 42.59%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Ergomed beats Avacta Group on 8 of the 14 factors compared between the two stocks.

How does Avacta Group compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Silence Therapeutics has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Avacta Group	£113K	2,878.88	-£30.08M	-£9.66	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

3.1% of Avacta Group shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

In the previous week, Avacta Group had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Avacta Group	Neutral

Summary

Avacta Group beats Silence Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
Avacta Group	£113K	2,878.88	-£30.08M	-£9.66	N/A

3.1% of Avacta Group shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Avacta Group had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
Avacta Group	Neutral

Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 42.59%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

Summary

Avacta Group beats Horizon Discovery Group plc (HZD.L) on 7 of the 12 factors compared between the two stocks.

Get Avacta Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVCT vs. The Competition

Export

Metric	Avacta Group	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£325.31M	£517.04M	£7.05B	£2.85B
Dividend Yield	3.97%	3.90%	2.68%	6.17%
P/E Ratio	-7.19	3.47	27.15	368.18
Price / Sales	2,878.88	6,436.17	587.92	84,612.72
Price / Cash	15.00	13.13	29.22	27.87
Price / Book	4.71	85.93	10.75	7.49
Net Income	-£30.08M	-£96.07M	£3.58B	£5.89B
7 Day Performance	-1.45%	-0.93%	-2.07%	-0.19%
1 Month Performance	-1.90%	2.45%	3.31%	-1.00%
1 Year Performance	116.97%	60.19%	26.35%	61.67%

Avacta Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVCT Avacta Group	1.6339 of 5 stars	GBX 69.43 +1.4%	GBX 99 +42.6%	+114.8%	£325.31M	£113K	N/A	120
ONT Oxford Nanopore Technologies	2.7547 of 5 stars	GBX 120.30 +1.2%	GBX 218.60 +81.7%	-27.4%	£1.17B	£223.90M	N/A	1,281	News Coverage Analyst Forecast
OXB Oxford Biomedica	0.6263 of 5 stars	GBX 611 +0.2%	GBX 600.04 -1.8%	+85.8%	£739.54M	£168.74M	N/A	891	Gap Down
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:AVCT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avacta Group (AVCT) Competitors

AVCT vs. ONT, OXB, ERGO, SLN, and HZD

How does Avacta Group compare to Oxford Nanopore Technologies?

Summary

How does Avacta Group compare to Oxford Biomedica?

Summary

How does Avacta Group compare to Ergomed?

Summary

How does Avacta Group compare to Silence Therapeutics?

Summary

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVCT vs. The Competition

Avacta Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avacta Group (AVCT) Competitors

AVCT vs. ONT, OXB, ERGO, SLN, and HZD

How does Avacta Group compare to Oxford Nanopore Technologies?

Do insiders & institutionals have more ownership in AVCT or ONT?

Which has more volatility and risk, AVCT or ONT?

Do analysts recommend AVCT or ONT?

Is AVCT or ONT more profitable?

Which has higher valuation and earnings, AVCT or ONT?

Does the media favor AVCT or ONT?

Summary

How does Avacta Group compare to Oxford Biomedica?

Does the media refer more to OXB or AVCT?

Do insiders and institutionals believe in OXB or AVCT?

Which has more risk and volatility, OXB or AVCT?

Which has better valuation & earnings, OXB or AVCT?

Do analysts rate OXB or AVCT?

Is OXB or AVCT more profitable?

Summary

How does Avacta Group compare to Ergomed?

Which has stronger valuation and earnings, ERGO or AVCT?

Is ERGO or AVCT more profitable?

Which has more risk and volatility, ERGO or AVCT?

Does the media prefer ERGO or AVCT?

Do insiders & institutionals hold more shares of ERGO or AVCT?

Do analysts recommend ERGO or AVCT?

Summary

How does Avacta Group compare to Silence Therapeutics?

Which has better earnings and valuation, SLN or AVCT?

Do analysts prefer SLN or AVCT?

Do institutionals and insiders have more ownership in SLN or AVCT?

Is SLN or AVCT more profitable?

Does the media prefer SLN or AVCT?

Summary

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Which has higher valuation and earnings, HZD or AVCT?

Do institutionals & insiders have more ownership in HZD or AVCT?

Does the media prefer HZD or AVCT?

Do analysts prefer HZD or AVCT?

Is HZD or AVCT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVCT vs. The Competition

Avacta Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools